In the news release, AbbVie, Inc.'s Zymaxid ™ Implicated in
Product Liability Lawsuit Due to Risk of Serious Injury and Death,
issued 02-Jul-2024 by Wormington
& Bollinger over PRWeb, the source of the release should be
"Wormington & Bollinger" rather than "AbbVie, Inc." as
incorrectly transmitted by PRWeb. Additionally, the headline has
been updated to further clarify the sourcing. The complete,
corrected release follows:
Wormington & Bollinger: AbbVie, Inc.'s Zymaxid ™ Implicated in
Product Liability Lawsuit Due to Risk of Serious Injury and Death
AbbVie faces lawsuit over Zymaxid™.
MCKINNEY, Texas, July 2, 2024
/PRNewswire-PRWeb/ -- Wormington & Bollinger is actively
reviewing product liability cases associated with antibiotic
eyedrops causing Stevens-Johnson Syndrome (SJS) and Toxic Epidermal
Necrolysis (TEN).
AbbVie, Inc. (NYSE: ABBV), a pharmaceutical company
headquartered in Chicago,
Illinois, is facing a product liability lawsuit, filed by
plaintiff, Alicia Burton in
Los Angeles, California. Burton
alleges that she sustained catastrophic injuries
stemming from the use of AbbVie's ophthalmic medication, Zymaxid™
(topical gatifloxacin).
In Alicia Burton v. Allergan,
Inc. and AbbVie, Inc. Case No. 2:22-cv-05920 in the U.S. District
Court for the Central District of California, the plaintiff alleges
that she suffered from SJS and TEN in 2019 after using AbbVie's
Zymaxid™ eye drops. This resulted in severe ocular injuries,
disfiguring scarring and permanently disabling injuries.
SJS and TEN are severe life-threatening reactions to medications
with mortality rates as high as 70%, often resulting in permanent
blindness, skin detachment, and irreversible physical disfigurement
from burns.
AbbVie's prescription medication, Zymaxid™, is a quinolone
antibiotic in eye drop form. While antibiotics taken orally and by
IV have been long implicated as a common cause of SJS and TEN,
cases caused by eye drop formulations of different antibiotics are
on the rise.
AbbVie manufactures antibiotic eye drops marketed under the
following trade names: Zymaxid™, Zymar™, Ocuflox™, Bleph-10™, and
Blephamide™.
Consumers should seek medical attention immediately upon
experiencing any of the symptoms listed above. Consumers
experiencing SJS and TEN caused by antibiotic eyedrops or other
prescription drugs are urged to contact Wormington & Bollinger
for a free case evaluation.
About Wormington & Bollinger
Lennie F. Bollinger is an
attorney headquartered in McKinney,
Texas. Mr. Bollinger serves clients across the U.S. in cases
involving personal injury, medical malpractice, pharmaceutical and
drug-device litigation, truck wrecks, product liability, premises
liability, and multi-district litigation.
Media Contact
Jeremy Friesen, Wormington &
Bollinger, 1 888-967-6529, jeremy@Wormingtonlegal.com,
https://www.wormingtonlegal.com/
View original content to download
multimedia:https://www.prweb.com/releases/abbvie-incs-zymaxid--implicated-in-product-liability-lawsuit-due-to-risk-of-serious-injury-and-death-302187623.html
SOURCE Wormington & Bollinger